InflaRx (NASDAQ:IFRX) highlighted recent clinical updates and strategic priorities for its complement inhibition platform during a presentation at Oppenheimer’s 36th Annual Healthcare Life Sciences ...
Vilobelimab is the first authorized drug to control complement factor C5a, a protein that plays an important and often harmful role in the body's immune response FDA granted EUA based on Phase III ...
InflaRx announces positive phase IIa top-line results from the SCIENS trial investigating IFX-1, a first-in-class anti-complement C5a antibody Jena, Germany, January 28th 2016 - InflaRx, a ...
JENA, Germany, July 30, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced it ...
Please provide your email address to receive an email when new articles are posted on . Targeting the complement pathway using a C5a agonist may be a “game changer” in anti-neutrophil cytoplasmic ...
Significantly elevated baseline C5a levels occur in hidradenitis suppurativa (HS) patients Vilobelimab dose-dependently suppresses C5a levels over time accompanied by the previously reported reduction ...
It is known that dendritic cells and innate lymphoid cells type 2 (ILC2) play key roles in allergen sensitization, and humoral factors such as complement C3a and complement C5a are highly involved in ...
The FDA’s Arthritis Advisory Committee panelists groped through cloudy data while complaining about the design of the phase III trial for Chemocentryx Inc.’s avacopan, and after going overtime ended ...
TSP-1 reduced C3 and C5 cleavage and formation of the membrane attack complex, attenuating complement-mediated injury in AAV models. Complement activation is a relevant driver in the pathomechanisms ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results